MARKET

ALKS

ALKS

Alkermes Plc
NASDAQ
30.10
-0.63
-2.05%
After Hours: 30.10 0 0.00% 16:19 02/27 EST
OPEN
30.35
PREV CLOSE
30.73
HIGH
30.49
LOW
29.91
VOLUME
2.49M
TURNOVER
--
52 WEEK HIGH
36.32
52 WEEK LOW
25.17
MARKET CAP
4.97B
P/E (TTM)
21.02
1D
5D
1M
3M
1Y
5Y
1D
Alkermes’ ALKS 2680 Narcolepsy Study Completion: What Investors Should Watch Next
TipRanks · 5h ago
Will Debt-Funded Avadel Deal and 2026 CEO Shift Change Alkermes' (ALKS) Narrative?
Simply Wall St · 23h ago
4 Analysts Have This To Say About Alkermes
Benzinga · 1d ago
Alkermes Price Target Raised to $43.00/Share From $37.00 by Wells Fargo
Dow Jones · 1d ago
Alkermes Is Maintained at Overweight by Wells Fargo
Dow Jones · 1d ago
Wells Fargo Maintains Overweight on Alkermes, Raises Price Target to $43
Benzinga · 1d ago
Alkermes Is Maintained at Outperform by RBC Capital
Dow Jones · 1d ago
Alkermes Price Target Cut to $45.00/Share From $47.00 by RBC Capital
Dow Jones · 1d ago
More
About ALKS
Alkermes plc is Ireland-based biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.

Webull offers Alkermes Plc stock information, including NASDAQ: ALKS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALKS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ALKS stock methods without spending real money on the virtual paper trading platform.